These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24225128)

  • 21. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
    Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
    Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides.
    López-Vicario C; Alcaraz-Quiles J; García-Alonso V; Rius B; Hwang SH; Titos E; Lopategi A; Hammock BD; Arroyo V; Clària J
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):536-41. PubMed ID: 25550510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.
    Luo P; Chang HH; Zhou Y; Zhang S; Hwang SH; Morisseau C; Wang CY; Inscho EW; Hammock BD; Wang MH
    J Pharmacol Exp Ther; 2010 Aug; 334(2):430-8. PubMed ID: 20439437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
    Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
    Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke.
    Zuloaga KL; Krasnow SM; Zhu X; Zhang W; Jouihan SA; Shangraw RE; Alkayed NJ; Marks DL
    PLoS One; 2014; 9(5):e97529. PubMed ID: 24824753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.
    Neckář J; Kopkan L; Husková Z; Kolář F; Papoušek F; Kramer HJ; Hwang SH; Hammock BD; Imig JD; Malý J; Netuka I; Ošťádal B; Červenka L
    Clin Sci (Lond); 2012 Jun; 122(11):513-25. PubMed ID: 22324471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors.
    Kundu B; Dvorácskó S; Basu A; Pommerolle L; Kim KA; Wood CM; Gibbs E; Behee M; Tarasova NI; Cinar R; Iyer MR
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
    Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
    Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.
    Katary MM; Pye C; Elmarakby AA
    Prostaglandins Other Lipid Mediat; 2017 Sep; 132():3-11. PubMed ID: 27596333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of soluble epoxide hydrolase inhibitors on the expression of fatty acid synthase in peripheral blood mononuclear cell of patients and inflammatory response with acute coronary syndrome].
    Du JQ; Peng R; Xu DY; Zhao TT; Shen L; Zhao SP
    Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(2):86-90. PubMed ID: 22490687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.
    Savina Y; Duflot T; Bounoure F; Kotzki S; Thiebaut PA; Serreau PA; Skiba M; Picquenot JM; Cornic M; Morisseau C; Hammock B; Imbert L; Cracowski JL; Richard V; Roustit M; Bellien J
    Diab Vasc Dis Res; 2019 Nov; 16(6):523-529. PubMed ID: 31267765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-4F Inhibits Oxidized Low-density Lipoprotein-induced Inflammatory Adipokine Secretion via Cyclic AMP/Protein Kinase A-CCAAT/Enhancer Binding Protein β Signaling Pathway in 3T3-L1 Adipocytes.
    Xie XZ; Huang X; Zhao SP; Yu BL; Zhong QQ; Cao J
    Chin Med J (Engl); 2016 May; 129(9):1108-12. PubMed ID: 27098798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1.
    Chui PC; Guan HP; Lehrke M; Lazar MA
    J Clin Invest; 2005 Aug; 115(8):2244-56. PubMed ID: 16007265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
    Honetschlägerová Z; Husková Z; Vaňourková Z; Sporková A; Kramer HJ; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Červenka L; Kopkan L
    J Physiol; 2011 Jan; 589(Pt 1):207-19. PubMed ID: 21078594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system.
    Varcabova S; Huskova Z; Kramer HJ; Hwang SH; Hammock BD; Imig JD; Kitada K; Cervenka L
    Clin Exp Pharmacol Physiol; 2013 Apr; 40(4):273-81. PubMed ID: 23039246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.
    Zhao X; Du JQ; Xu DY; Zhao SP
    Lipids Health Dis; 2013 Jan; 12():3. PubMed ID: 23305094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
    Kala P; Sedláková L; Škaroupková P; Kopkan L; Vaňourková Z; Táborský M; Nishiyama A; Hwang SH; Hammock BD; Sadowski J; Melenovský V; Imig JD; Červenka L
    Physiol Res; 2018 Jul; 67(3):401-415. PubMed ID: 29527914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
    Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
    Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes.
    Kuniyasu A; Tokunaga M; Yamamoto T; Inoue S; Obama K; Kawahara K; Nakayama H
    Biochim Biophys Acta; 2011 Mar; 1811(3):153-62. PubMed ID: 21146630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.